The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer

Goel, Anupama; Phillips, John L.; Ennis, Ronald D.; Grossbard, Michael L.

doi:10.1634/theoncologist.11-6-630

Cited by 18 publications

(10 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These patients are potential candidates for intensive adjuvant therapy including clinical trials. Although adjuvant chemotherapy for patients with high‐risk disease after immediate RC is still controversial [23], a recent randomized phase III study showed significant improvement of OS and CSS in patients receiving a combination of paclitaxel, gemcitabine and cisplatin [24]. A major cause of concern in adjuvant settings after salvage cystectomy, however, is potential cross‐resistance of micrometastasis from bladder cancer cells resistant to induction CRT.…”

Section: Discussionmentioning

confidence: 99%

Pathology‐based risk stratification of muscle‐invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder‐sparing approaches

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pathology‐based risk stratification of muscle‐invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder‐sparing approaches

et al. 2012

View full text Add to dashboard Cite

show abstract

“…While cisplatin-based chemotherapy is a standard treatment in metastatic bladder cancer, there is some debate about the use of adjuvant chemotherapy for patients with locally advanced disease after radical cystectomy (39,40). In recent trial updates, cisplatin-based combination chemotherapy was able to produce longterm disease-free survival in some groups of patients (41)(42)(43).…”

Section: Discussionmentioning

confidence: 99%

A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

Kim

Jeong

et al. 2011

Mol Med

View full text Add to dashboard Cite

There are no reliable criteria to handle disease progression of muscle invasive bladder cancer (MIBC), which strongly influences patient survival. Therefore, an accurate predicting method to identify progressive MIBC patients is greatly needed. The aim of this study was to identify a genetic signature associated with disease progression in MIBC. To address this issue, we analyzed three independent cohorts (a training set, test set 1 and test set 2) comprising a total of 128 MIBC patients. Microarray gene expression profiling, including gene network analysis, was performed in the training set to identify a gene expression signature associated with disease progression. The prognostic value of the signature was validated in test set 1 and test set 2 by microarray and real-time reverse transcriptase polymerase chain reaction (RT-PCR), respectively. The determination of gene expression patterns by microarray data analysis identified 1,320 genes associated with disease progression. Gene network analysis of the 1,320 genes suggested that IL1B, S100A8, S100A9 and EGFR were important mediators of MIBC progression. We validated this putative four-gene signature in two independent cohorts (log-rank test, P < 0.05 each, respectively) and estimated the predictive value of the signature by multivariate Cox regression analysis (hazard ratio [HR], 6.24; 95% confidence interval [CI], 1.58-24.61; P = 0.009). Finally, signature-based stratification demonstrated that the four-gene signature was an independent predictor of MIBC progression. In conclusion, a molecular signature defined by four genes represents a promising diagnostic tool for the identification of MIBC patients at high risk of progression.

show abstract

“…Die Rate an sekundär notwendigen Salvage-Zystektomien liegt zwischen 10-30 % [15,21,25]. Dabei scheint sich die Komplikationsrate nicht wesentlich von der einer primären Zystektomie zu unterscheiden [26].…”

Section: Multimodale Therapie (Mmt)unclassified

Organerhaltende Therapieoptionen des muskelinvasiven Harnblasenkarzinoms

Kempkensteffen¹

2017

Klinikarzt

View full text Add to dashboard Cite

ZusammenfassungDie radikale Zystektomie gilt gemäß nationaler und internationaler Leitlinien als Therapie der Wahl zur Behandlung des muskelinvasiven Harnblasenkarzinoms. Insbesondere bei alten, komorbiden Patienten ist dieser Eingriff jedoch mit einem relativ hohen Komplikationsrisiko assoziiert. Jüngere Patienten befürchten darüber hinaus vor allem postoperative Einschränkungen der Lebensqualität durch Störungen der Sexualität, der Kontinenz und des Körperbildes infolge der möglicherweise notwendigen Anlage eines Urostomas. Daraus resultiert eine zunehmende Nachfrage nach alternativen, organerhaltenden Therapieoptionen. Hier stehen derzeit die multimodale Therapie und die partielle Zystektomie im Vordergrund. Unter der Voraussetzung einer stringenten Patientenselektion sowie einer engmaschigen Tumornachsorge, lassen sich mit beiden Verfahren der radikalen Zystektomie vergleichbare onkologische Ergebnisse erreichen.

show abstract

The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer

Cited by 18 publications

References 74 publications

Pathology‐based risk stratification of muscle‐invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder‐sparing approaches

Pathology‐based risk stratification of muscle‐invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder‐sparing approaches

A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

Organerhaltende Therapieoptionen des muskelinvasiven Harnblasenkarzinoms

Contact Info

Product

Resources

About